Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (IV) ##STR00001##
wherein R.sub.1 and R.sub.2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.

The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases oR disorders mediated by CD47.

The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below: ##STR00001##
wherein the definitions of T, Q, R.sub.1 and R.sub.2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.

The present invention provides a substituted polypeptide having the effect of inhibiting MMP2 and represented by formula [I], or a pharmaceutically acceptable salt thereof.

##STR00001##

Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.

##STR00001##

Provided, inter alia, are antibody drug conjugates (ADCs) which specifically bind B Cell Maturation Antigen (BCMA). Further disclosed are pharmaceutical compositions, and methods for treating cancer.

We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (ARMD), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.

Disclosed herein are embodiments of compounds that can be used to target glutathione to various target sites, such as cells, mitochondria, and other organelles. Also disclosed herein are embodiments of methods for making and using the compounds. In particular disclosed embodiments, the compounds can be used to treat, ameliorate, and/or prevent diseases or conditions associated with low or reduced glutathione levels, as well as other types of diseases/conditions.

The present invention provides a crystal of reduced glutathione having excellent powder properties and a method for producing the same. The present invention relates to a crystal of reduced glutathione, wherein the average crystal thickness is 10 ?m or more.

The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.